アルテミシニン併用療法市場：タイプ、用途、流通チャネル、患者年齢層、剤形、治療タイプ別-2025-2030年世界予測

アルテミシニン併用療法市場は、2023年に3億4,118万米ドルと評価され、2024年には3億6,234万米ドルに達すると予測され、CAGR 6.46％で成長し、2030年には5億2,904万米ドルに達すると予測されています。

アルテミシニン併用療法（ACT）は、アルテミシニン誘導体とパートナー薬剤を併用することで、有効性を高め、耐性発現を抑える抗マラリア治療薬です。ACTの必要性は、マラリア原虫に感染した患者の寄生虫量を迅速に減少させる優れた有効性と、マラリアと闘う世界の取り組みにおける重要な役割にあります。最終用途の範囲は、主にマラリア流行地域のヘルスケア環境であり、病院、診療所、地域保健プログラムが含まれます。市場成長を促進する主な要因としては、世界のマラリア負担の増加、国際保健機関からの資金提供の増加、マラリア対策プログラムを強化するための政府の取り組みなどが挙げられます。また、認知度の向上や農村部でのアクセスを容易にするサプライチェーン・ロジスティクスの改善による需要の高まりもあります。しかし市場は、部分的なアルテミシニン耐性の出現、併用療法の高コスト、承認取得における規制上のハードルなど、大きな課題に直面しています。新たな薬剤製剤の開発や、的確なマラリア管理のための高度な診断ツールとの併用によるACTの使用拡大には機会が存在します。このような機会を捉えるため、企業は合成誘導体や新規ドラッグデリバリープラットフォームの開発など、耐性克服とコスト削減を目指した研究と技術革新に注力すべきです。また、公衆衛生イニシアティブとのパートナーシップを促進することで、普及と採用において大きなアドバンテージを得ることができます。市場力学は複雑で、地域情勢別疾病発生率、資金調達レベル、規制環境に影響されるため、変化する状況に適応するための機敏なビジネス戦略が必要となります。耐性と費用対効果の制約の中でイノベーションを起こすことが極めて重要であるため、バイオ強化ジェネリック医薬品や、新たなデジタルヘルスプラットフォームとの統合ソリューションの研究が、大きな進歩の先駆けとなる可能性があります。全体として、ACT市場は活気に満ちているが課題も多く、持続的な成長とインパクトをもたらすためには戦略的洞察力と革新的なアプローチが必要です。

市場力学：急速に進化するアルテミシニン併用療法市場の主要市場インサイトを公開

アルテミシニン併用療法市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • マラリアの蔓延によるアルテミシニン併用療法の需要増加
  • アルテミシニン併用治療の使用を促進する政府の取り組み
  • マラリア治療における併用療法の利点に関する意識の高まり
• 市場抑制要因
  • 高い製造コストとサプライチェーンの非効率性
• 市場機会
  • 抗マラリア薬研究に対する政府および民間セクターの投資の活発化
  • 製薬会社と研究機関の連携やパートナーシップの増加
• 市場の課題
  • アルテミシニン併用療法の世界的流通に関する規制上のハードル

ポーターの5つの力アルテミシニン併用療法市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、アルテミシニン併用療法市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アルテミシニン併用療法市場における外部からの影響の把握

外部マクロ環境要因は、アルテミシニン併用療法市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アルテミシニン併用療法市場における競合情勢の把握

アルテミシニン併用療法市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアルテミシニン併用療法市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アルテミシニン併用療法市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アルテミシニン併用療法市場における成功への道筋を描く

アルテミシニン併用療法市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • マラリアの蔓延によりアルテミシニン併用療法の需要が増加
    • アルテミシニン併用療法の使用を促進する政府の取り組み
    • マラリア治療における併用療法の利点についての認識の高まり
  • 抑制要因
    • 高い生産コストとサプライチェーンの非効率性
  • 機会
    • 抗マラリア薬調査への政府と民間部門の投資の強化
    • 製薬企業と調査機関の連携とパートナーシップの増加
  • 課題
    • アルテミシニン併用療法の世界の流通に関する規制上のハードル
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アルテミシニン併用療法市場：タイプ別

• アルテメテル-ルメファントリン
• アルテスネート-アモジアキン
• アルテスネート-メフロキン
• アルテスネートピロナリジン
• ジヒドロアルテミシニン-ピペラキン

第7章 アルテミシニン併用療法市場：用途別

• クリニック
• 病院
• 家庭用
• 調査機関

第8章 アルテミシニン併用療法市場：流通チャネル別

• ドラッグストア
• 病院薬局
• オンライン薬局
• 小売薬局

第9章 アルテミシニン併用療法市場患者の年齢層別

• 成人用
• 高齢者
• 小児科

第10章 アルテミシニン併用療法市場処方別

• カプセル
• 注射
• サスペンション
• 錠剤

第11章 アルテミシニン併用療法市場治療の種類別

• 併用療法
• 第一選択療法
• モノセラピー
• 第二選択療法

第12章 南北アメリカのアルテミシニン併用療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のアルテミシニン併用療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのアルテミシニン併用療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Ajanta Pharma Limited
• 2. Aurobindo Pharma Limited
• 3. Cipla Limited
• 4. Dafra Pharma International NV
• 5. F. Hoffmann-La Roche AG
• 6. GlaxoSmithKline plc
• 7. Guilin Pharmaceutical Co., Ltd.
• 8. Ipca Laboratories Limited
• 9. KPC Pharmaceuticals, Inc.
• 10. Merck & Co., Inc.
• 11. Mylan N.V.
• 12. Novartis International AG
• 13. Pfizer Inc.
• 14. Ranbaxy Laboratories Limited
• 15. Sanofi S.A.
• 16. Shin Poong Pharmaceutical Co., Ltd.
• 17. Strides Pharma Science Limited
• 18. Sumaya Biotech Pvt. Ltd.
• 19. Turing Pharmaceuticals AG
• 20. Zydus Cadila

LIST OF FIGURES

• FIGURE 1. ARTEMISININ COMBINATION THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ARTEMISININ COMBINATION THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ARTEMISININ COMBINATION THERAPY MARKET DYNAMICS
• TABLE 7. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTEMETHER-LUMEFANTRINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-AMODIAQUINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-MEFLOQUINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ARTESUNATE-PYRONARIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DIHYDROARTEMISININ-PIPERAQUINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOUSEHOLD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FIRST-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY MONO THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY SECOND-LINE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 60. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 61. CANADA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 92. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 93. CHINA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 98. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 99. INDIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 104. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 105. INDONESIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 109. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 110. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 111. JAPAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 115. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 116. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 117. MALAYSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 121. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 122. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 123. PHILIPPINES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 127. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 128. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 129. SINGAPORE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 139. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 140. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 141. TAIWAN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 145. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 146. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 147. THAILAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 151. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 152. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 153. VIETNAM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 158. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 165. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 166. DENMARK ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 171. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 172. EGYPT ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 177. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 178. FINLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 182. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 183. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 184. FRANCE ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 189. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 190. GERMANY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 195. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 196. ISRAEL ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 198. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 200. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 201. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 202. ITALY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 206. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 207. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 208. NETHERLANDS ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 212. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 213. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 214. NIGERIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 218. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 219. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 220. NORWAY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 222. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 224. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 225. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 226. POLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 228. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 230. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 231. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 232. QATAR ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 236. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 237. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 238. RUSSIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 242. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 243. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 244. SAUDI ARABIA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 248. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 249. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 250. SOUTH AFRICA ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 254. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 255. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 256. SPAIN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 260. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 261. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 262. SWEDEN ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 266. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 267. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 268. SWITZERLAND ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 272. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 273. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 274. TURKEY ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 278. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 279. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 280. UNITED ARAB EMIRATES ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 284. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
• TABLE 285. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 286. UNITED KINGDOM ARTEMISININ COMBINATION THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 287. ARTEMISININ COMBINATION THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 288. ARTEMISININ COMBINATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

The Artemisinin Combination Therapy Market was valued at USD 341.18 million in 2023, expected to reach USD 362.34 million in 2024, and is projected to grow at a CAGR of 6.46%, to USD 529.04 million by 2030.

Artemisinin Combination Therapy (ACT) is an antimalarial treatment that combines an artemisinin derivative with a partner drug to enhance efficacy and reduce resistance development. The necessity of ACT arises from its superior efficacy in rapidly reducing the parasite biomass in patients infected with Plasmodium falciparum and its critical role in global efforts to combat malaria. The application and end-use scope primarily extend to healthcare settings in malaria-endemic regions, involving hospitals, clinics, and community health programs. Key factors driving market growth include the global malaria burden, increased funding from international health organizations, and government initiatives to enhance malaria control programs. There's also rising demand due to increased awareness and improved supply chain logistics facilitating rural access. However, the market faces significant challenges such as the emergence of partial artemisinin resistance, the high cost of combination therapies, and regulatory hurdles in obtaining approvals. Opportunities exist in the development of newer drug formulations and the expansion of ACT use in combination with advanced diagnostic tools for precise malaria management. To seize these opportunities, companies should focus on research and innovation aimed at overcoming resistance and decreasing costs, such as developing synthetic derivatives or novel drug delivery platforms. Encouraging partnerships with public health initiatives can also provide a substantial advantage in dissemination and adoption. The market dynamics are complex, influenced by geographical disease incidence, funding levels, and regulatory environments, which necessitate agile business strategies to adapt to changing landscapes. Innovating within the constraints of resistance and cost-effectiveness will be crucial; therefore, research on bio-enhanced generics or integrative solutions with emerging digital health platforms could usher in significant advancements. Overall, the ACT market is vibrant yet challenging, requiring strategic insights and innovative approaches for sustained growth and impact.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Artemisinin Combination Therapy Market

The Artemisinin Combination Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
  • Government initiatives promoting the use of artemisinin combination treatments
  • Rising awareness about the advantages of combination therapy for malaria treatment
• Market Restraints
  • High production costs and supply chain inefficiencies
• Market Opportunities
  • Heightened government and private sector investments in antimalarial drug research
  • Rising collaborations and partnerships between pharmaceutical companies and research institutes
• Market Challenges
  • Regulatory hurdles related to the global distribution of artemisinin combination therapy

Porter's Five Forces: A Strategic Tool for Navigating the Artemisinin Combination Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Artemisinin Combination Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Artemisinin Combination Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Artemisinin Combination Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Artemisinin Combination Therapy Market

A detailed market share analysis in the Artemisinin Combination Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Artemisinin Combination Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Artemisinin Combination Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Artemisinin Combination Therapy Market

A strategic analysis of the Artemisinin Combination Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Artemisinin Combination Therapy Market, highlighting leading vendors and their innovative profiles. These include Ajanta Pharma Limited, Aurobindo Pharma Limited, Cipla Limited, Dafra Pharma International NV, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Guilin Pharmaceutical Co., Ltd., Ipca Laboratories Limited, KPC Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Shin Poong Pharmaceutical Co., Ltd., Strides Pharma Science Limited, Sumaya Biotech Pvt. Ltd., Turing Pharmaceuticals AG, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Artemisinin Combination Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-Mefloquine, Artesunate-Pyronaridine, and Dihydroartemisinin-Piperaquine.
• Based on Application, market is studied across Clinic, Hospital, Household, and Research Institute.
• Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Patient Age Group, market is studied across Adult, Geriatric, and Pediatric.
• Based on Formulation, market is studied across Capsule, Injection, Suspension, and Tablet.
• Based on Therapy Type, market is studied across Combination Therapy, First-Line Therapy, Mono Therapy, and Second-Line Therapy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of malaria leading to increased demand for artemisinin combination therapy
    • 5.1.1.2. Government initiatives promoting the use of artemisinin combination treatments
    • 5.1.1.3. Rising awareness about the advantages of combination therapy for malaria treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High production costs and supply chain inefficiencies
  • 5.1.3. Opportunities
    • 5.1.3.1. Heightened government and private sector investments in antimalarial drug research
    • 5.1.3.2. Rising collaborations and partnerships between pharmaceutical companies and research institutes
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles related to the global distribution of artemisinin combination therapy
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Artemisinin Combination Therapy Market, by Type

• 6.1. Introduction
• 6.2. Artemether-Lumefantrine
• 6.3. Artesunate-Amodiaquine
• 6.4. Artesunate-Mefloquine
• 6.5. Artesunate-Pyronaridine
• 6.6. Dihydroartemisinin-Piperaquine

7. Artemisinin Combination Therapy Market, by Application

• 7.1. Introduction
• 7.2. Clinic
• 7.3. Hospital
• 7.4. Household
• 7.5. Research Institute

8. Artemisinin Combination Therapy Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Drug Stores
• 8.3. Hospital Pharmacies
• 8.4. Online Pharmacies
• 8.5. Retail Pharmacies

9. Artemisinin Combination Therapy Market, by Patient Age Group

• 9.1. Introduction
• 9.2. Adult
• 9.3. Geriatric
• 9.4. Pediatric

10. Artemisinin Combination Therapy Market, by Formulation

• 10.1. Introduction
• 10.2. Capsule
• 10.3. Injection
• 10.4. Suspension
• 10.5. Tablet

11. Artemisinin Combination Therapy Market, by Therapy Type

• 11.1. Introduction
• 11.2. Combination Therapy
• 11.3. First-Line Therapy
• 11.4. Mono Therapy
• 11.5. Second-Line Therapy

12. Americas Artemisinin Combination Therapy Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Artemisinin Combination Therapy Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Artemisinin Combination Therapy Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Ajanta Pharma Limited
• 2. Aurobindo Pharma Limited
• 3. Cipla Limited
• 4. Dafra Pharma International NV
• 5. F. Hoffmann-La Roche AG
• 6. GlaxoSmithKline plc
• 7. Guilin Pharmaceutical Co., Ltd.
• 8. Ipca Laboratories Limited
• 9. KPC Pharmaceuticals, Inc.
• 10. Merck & Co., Inc.
• 11. Mylan N.V.
• 12. Novartis International AG
• 13. Pfizer Inc.
• 14. Ranbaxy Laboratories Limited
• 15. Sanofi S.A.
• 16. Shin Poong Pharmaceutical Co., Ltd.
• 17. Strides Pharma Science Limited
• 18. Sumaya Biotech Pvt. Ltd.
• 19. Turing Pharmaceuticals AG
• 20. Zydus Cadila